| Literature DB >> 27464679 |
Fiammetta Maria Bozzani1,2, Matthias Arnold3,4, Timothy Colbourn5, Norman Lufesi6, Bejoy Nambiar5,7, Gibson Masache7, Jolene Skordis-Worrall5.
Abstract
BACKGROUND: Human resources are a major cost driver in childhood pneumonia case management. Introduction of 13-valent pneumococcal conjugate vaccine (PCV-13) in Malawi can lead to savings on staff time and salaries due to reductions in pneumonia cases requiring admission. Reliable estimates of human resource costs are vital for use in economic evaluations of PCV-13 introduction.Entities:
Keywords: Children; Malawi; PCV-13; Pneumococcal conjugate vaccine; Pneumonia; Provider costs; Time use
Mesh:
Substances:
Year: 2016 PMID: 27464679 PMCID: PMC4964305 DOI: 10.1186/s12913-016-1573-5
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Description of activities and staff involved in the management of under-5 pneumonia inpatients
| Activities | Personnel |
|
|---|---|---|
| Assessment, monitoring and stabilisinga | Senior clinical cadres | |
| OPD assessment/admission | Nursing officer | 1 |
| Monitoring oxygen saturation | Senior clinical technician | 1 |
| Oxygen therapy | Other clinical cadres | |
| Monitoring vital signs | Clinical technician | 4 |
| Intravenous fluid infusion | Nurse technician | 12 |
| Oral rehydration | Medical assistant | 8 |
| Administering injections | Auxiliary nurse | 1 |
| Benzylpenicillin | Health surveillance assistant | 1 |
| Chloramphenicol | Support staff | |
| Ceftriaxone | Hospital attendant | 1 |
| Gentamicin | Ward clerk | 1 |
| Administering other drugs | ||
| Paracetamol | ||
| Cotrimoxazole | ||
| Salbutamol | ||
| Aminophylline | ||
| Quinine | ||
| Artemisinin-based combination therapy | ||
| Diagnostic tests | ||
| HIV antibody test | ||
| Malaria blood film | ||
| Administrative tasks | ||
| Ward round | ||
| Discharge paperwork | ||
| Other paperwork | ||
| Setting review appointment |
a during the study period, no x-ray facilities were available at Mchinji District Hospital
Fig. 1Description of reported activities by type (n = 1071)
Time spent on individual activities for severe (n = 28) and very severe inpatients (n = 24)
| Severe | Very severe | ||||
|---|---|---|---|---|---|
|
| Mean (SD) |
| Mean (SD) |
| |
| Injecting antibiotics | 241 | 25.78 (16.63) | 42 | 29.16 (18.35) | 0.24 |
| Oral medications | 177 | 15.21 (9.34) | 159 | 16.42 (14.26) | 0.36 |
| OPD assessment | 28 | 12.70 (9.93) | 24 | 9.1 (8.45) | 0.08 |
| Monitoring oxygen saturation | 21 | 7.25 (10.94) | 67 | 9.71 (10.97) | 0.21 |
| Ward round | 49 | 4.78 (4.04) | 48 | 5.37 (7.60) | 0.36 |
| Oxygen therapy | 5 | 0.36 (0.95) | 20 | 4.87 (8.45) | 0.001 |
| Discharge/paperwork | 45 | 3.36 (2.23) | 50 | 2.71 (3.03) | 0.50 |
| Monitoring vital signs | 12 | 1.25 (3.48) | 10 | 1.46 (2.22) | 0.40 |
| Intra-venous fluid | 3 | 0.32 (1.06) | 3 | 1.79 (6.09) | 0.11 |
| Diagnostic tests | 3 | 0.42 (1.26) | 5 | 0.75 (1.73) | 0.22 |
| Administering antimalarials | 5 | 0.28 (1.01) | 0 | 0 (0) | 0.08 |
| TOTAL | 589 | 93.14 (37.99) | 428 | 106.43 (54.76) | 0.15 |
N total observations for each activity, OPD out-patient department
Injecting antibiotics: benzylpenicillin, chloramphenicol, ceftriaxone, gentamicin
Oral medications: paracetamol, cotrimoxazole, salbutamol, aminophylline
Antimalarials: artemisinin-based combination therapy, quinine. Diagnostic tests: malaria blood film, HIV antibody test
* T-test for a difference in mean time spent on activity between severe and very severe cases
Human resources time and costs for severe and very severe pneumonia case management at Mchinji District Hospital
| All | Severe pneumonia | Very severe pneumonia |
| |
|---|---|---|---|---|
| Mean time (SD), minutes | ||||
| Senior clinical cadres | 3.26 (8.22) | 2.93 (7.94) | 3.67 (8.68) | 0.37 |
| Clinical cadres | 73.27 (34.76) | 72.29 (37.68) | 74.42 (31.76) | 0.41 |
| Support staff | 11.44 (14.98) | 7.28 (7.27) | 16.29 (19.75) | 0.01 |
| HR costs, US$ | ||||
| Cost per child | 30.99 | 29.52 | 32.69 | |
| Annual costs | 24,947 | 14,817 | 9,906 | |
| One-way sensitivity analysis | ||||
| Annual cost savings (range) | 6,439 | |||
| a | (2,179–9,906) | |||
| b | (−978–11,495) |
a Based on PCV-13 vaccine efficacy estimates of 65 % (range: 22–100 %) against all-cause very severe pneumonia and 0 % against all-cause severe pneumonia (McCollum ED, Nambiar, B, et al. Impact of the 13-valent pneumococcal conjugate vaccine on clinical and hypoxemic childhood pneumonia at the community, health centre and hospital levels over three years in Malawi: a time series analysis of two districts, under review)
b Based on a +/− 25 % increase in the annual number of pneumonia inpatients under five years of age